Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

News SummaryMost relevantAll newsSector newsTweets 

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
01/18/2013 | 02:46pm CEST
   By Saabira Chaudhuri 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER INC
12:06p PFIZER : Eliminating Diseases Through Vaccination
10:42a PFIZER : Aquinnah Pharmaceuticals Receives $10M Investment from Pfizer and Abbvi..
10:39a PFIZER : Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer an..
04/25 AQUINNAH PHARMACEUTICALS : Receives $10 Million Investment from Pfizer and AbbVi..
04/24 PFIZER : Unveils ATLAS, An Interactive, User-Friendly Website That Provides Glob..
04/24 PFIZER : Receives Positive CHMP Opinion for BESPONSA (Inotuzumab Ozogamicin) for..
04/24 PFIZER : unveils global antibiotic resistance surveillance data site
04/24 KAROLINSKA DEVELOPMENT : Modus Therapeutics announces appointment of Ellen K. Do..
04/24 PFIZER : Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (cefta..
04/24 ROCHE : Pharmaceutical Freeze Drying Experts Gather in 2 weeks to discuss the Es..
More news
Sector news : Pharmaceuticals - NEC
02:00pDJGLAXOSMITHKLINE : Net Income Boosted by Strong Sales, Weak Pound
01:43p GLAXOSMITHKLINE : Weak sterling boosts GlaxSmithKline as new CEO takes over
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
04/25DJNasdaq Composite Tops 6000 for First Time
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2017 53 186 M
EBIT 2017 19 964 M
Net income 2017 11 673 M
Debt 2017 24 417 M
Yield 2017 3,78%
P/E ratio 2017 16,83
P/E ratio 2018 14,93
EV / Sales 2017 4,24x
EV / Sales 2018 3,98x
Capitalization 201 045 M
More Financials
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,8 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%201 045
JOHNSON & JOHNSON7.13%334 605
ROCHE HOLDING LTD.10.49%223 016
PFIZER INC.3.88%201 045
NOVARTIS AG2.16%199 772
MERCK & CO., INC.5.83%170 797
More Results